Henry Lowman, PhD
Scientific Advisory Board Member
Dr. Henry Lowman has more than 30 years’ experience in biotechnology with expertise in R&D of biotherapeutics. After earning a B.A. in chemistry at Johns Hopkins University and a Ph.D. in chemistry at Purdue University, he was named an NIH postdoctoral fellow at Genentech. He then moved on to scientist roles, before leading Genentech's antibody engineering department, with R&D team-leader roles in several therapeutic antibody programs, including VEGF, IgE, and CD20. He later served at CytomX Therapeutics as vice president of research and then chief scientific officer in work on the Probody™ platform, and at Triphase Accelerator as executive director/VP of R&D. In 2013 he was named one of the top 25 most influential individuals in the antibody field by Total Biopharma. He is an inventor on >700 filed/issued patents. Dr. Lowman is an editorial board member for the antibody journal mAbs and is currently an advisor/board member for several organizations.
Statement: “I am thrilled to join the scientific advisory board of Aarvik. This group of proven innovators will advance the next generation of ADCs and other therapeutic modalities and based on unique insights into the chemistry and biology of these agents.”